Tags

Type your tag names separated by a space and hit enter

Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Mov Disord. 2005 Sep; 20(9):1205-9.MD

Abstract

We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa-induced dyskinesias in Parkinson's disease (PD) in an open-label pilot study. Nine PD patients who were experiencing peak-dose dyskinesias for at least 25% of the awake day and were at least moderately disabling were treated with LEV in doses up to 3,000 mg for up to 60 days. The primary outcome measure was the percent of the awake day that patients spent on without dyskinesia or with nontroublesome dyskinesia (good on time). The mean dose of LEV at endpoint was 625+/-277 mg/day. LEV significantly improved percent of the awake day on without dyskinesia or with nontroublesome dyskinesia at endpoint compared to baseline (43% +/- 12% vs. 61% +/- 17%; P=0.02). Percent on time with troublesome dyskinesia decreased from 23% +/- 10% at baseline to 11% +/- 6% at endpoint, although not significantly. There was no significant increase in off time from baseline to endpoint. There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak-dose dyskinesia for at least 25% of the awake day, LEV significantly improved on time without dyskinesia or with nontroublesome dyskinesia.

Authors+Show Affiliations

Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 336112, USA. tzesiewi@hsc.usf.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15954135

Citation

Zesiewicz, Theresa A., et al. "Open-label Pilot Study of Levetiracetam (Keppra) for the Treatment of Levodopa-induced Dyskinesias in Parkinson's Disease." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 20, no. 9, 2005, pp. 1205-9.
Zesiewicz TA, Sullivan KL, Maldonado JL, et al. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord. 2005;20(9):1205-9.
Zesiewicz, T. A., Sullivan, K. L., Maldonado, J. L., Tatum, W. O., & Hauser, R. A. (2005). Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 20(9), 1205-9.
Zesiewicz TA, et al. Open-label Pilot Study of Levetiracetam (Keppra) for the Treatment of Levodopa-induced Dyskinesias in Parkinson's Disease. Mov Disord. 2005;20(9):1205-9. PubMed PMID: 15954135.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. AU - Zesiewicz,Theresa A, AU - Sullivan,Kelly L, AU - Maldonado,John L, AU - Tatum,William O, AU - Hauser,Robert A, PY - 2005/6/15/pubmed PY - 2005/12/21/medline PY - 2005/6/15/entrez SP - 1205 EP - 9 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 20 IS - 9 N2 - We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa-induced dyskinesias in Parkinson's disease (PD) in an open-label pilot study. Nine PD patients who were experiencing peak-dose dyskinesias for at least 25% of the awake day and were at least moderately disabling were treated with LEV in doses up to 3,000 mg for up to 60 days. The primary outcome measure was the percent of the awake day that patients spent on without dyskinesia or with nontroublesome dyskinesia (good on time). The mean dose of LEV at endpoint was 625+/-277 mg/day. LEV significantly improved percent of the awake day on without dyskinesia or with nontroublesome dyskinesia at endpoint compared to baseline (43% +/- 12% vs. 61% +/- 17%; P=0.02). Percent on time with troublesome dyskinesia decreased from 23% +/- 10% at baseline to 11% +/- 6% at endpoint, although not significantly. There was no significant increase in off time from baseline to endpoint. There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak-dose dyskinesia for at least 25% of the awake day, LEV significantly improved on time without dyskinesia or with nontroublesome dyskinesia. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/15954135/Open_label_pilot_study_of_levetiracetam__Keppra__for_the_treatment_of_levodopa_induced_dyskinesias_in_Parkinson's_disease_ L2 - https://doi.org/10.1002/mds.20563 DB - PRIME DP - Unbound Medicine ER -